C
Carlos A. Guzmán
Researcher at University of Genoa
Publications - 281
Citations - 10481
Carlos A. Guzmán is an academic researcher from University of Genoa. The author has contributed to research in topics: Immune system & Antigen. The author has an hindex of 54, co-authored 260 publications receiving 9506 citations. Previous affiliations of Carlos A. Guzmán include Hannover Medical School & Bill & Melinda Gates Foundation.
Papers
More filters
Patent
New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions
TL;DR: In this article, the bisacyloxycysteine type is used as adjuvants and immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies and for the control of fertility in human or animal populations.
Journal ArticleDOI
Replication-deficient mutant Herpes Simplex Virus-1 targets professional antigen presenting cells and induces efficient CD4+ T helper responses.
Simona Fiorentini,Peggy Marconi,Manuela Avolio,Elena Marini,Emirena Garrafa,Sonia Caracciolo,Daniele Rossi,Alexandra Bozac,Pablo D. Becker,Francesca Gentili,Fabio Facchetti,Carlos A. Guzmán,Roberto Manservigi,Arnaldo Caruso +13 more
TL;DR: It is shown that a recombinant replication-deficient Herpes Simplex Virus-1 vector encoding p17 (T0-p17) was capable of infecting professional antigen presenting cells (APCs) in vitro and in vivo, and can be appealing candidates for the development of vaccines able to trigger T helper responses.
Journal ArticleDOI
Distinct immunological and molecular signatures underpinning influenza vaccine responsiveness in the elderly
Peggy Riese,Stephanie Trittel,Manas K. Akmatov,Marcus May,Jana Prokein,Thomas Illig,Christoph Schindler,Birgit Sawitzki,Yassin Elfaki,Stefan Floess,Jochen Huehn,Adrian J. Błażejewski,Till Strowig,Esteban A. Hernandez-Vargas,Robert Geffers,Bowen Zhang,Yang Li,Frank Pessler,Carlos A. Guzmán +18 more
TL;DR: In this article , a comprehensive characterization of the immune response of randomly selected elderly participants (≥ 65 years), immunized with the adjuvanted influenza vaccine Fluad is presented.
Journal ArticleDOI
The FAI protein of group C streptococci targets B-cells and exhibits adjuvant activity.
TL;DR: The obtained results suggest that the FAI protein represents a useful tool to improve the immunogenicity of vaccine antigens.
Journal ArticleDOI
Peptidoglycan-treated tumor antigen-pulsed dendritic cells impart complete resistance against tumor rechallenge
Ashok Patidar,Sathishkumar Selvaraj,Prashant Chauhan,Carlos A. Guzmán,Thomas Ebensen,Arup Sarkar,Debprasad Chattopadhyay,Bhaskar Saha +7 more
TL;DR: A repetitive RM-1 murine tumor rechallenge model for recurrence in humans is described and observations indicate that PGN-activated DCs induce robust host-protective anti-tumor T cells that completely resist tumor growth and recurrence.